BFEC
CNCE

Benjamin F. Edwards & Company’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-300
Closed -$4K – 1600
2017
Q2 		$4K Hold
300
– – ﹤0.01% 1295
2017
Q1 		$5K Hold
300
– – ﹤0.01% 1173
2016
Q4 		$3K Hold
300
– – ﹤0.01% 1137
2016
Q3 		$3K Hold
300
– – ﹤0.01% 1026
2016
Q2 		$3K Hold
300
– – ﹤0.01% 983
2016
Q1 		$4K Buy
+300
New +$4.32K ﹤0.01% 960

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Benjamin F. Edwards & Company's CNCE Position: Q3 2017 in Review

Benjamin F. Edwards & Company sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 300 shares — an estimated $4K sold.

Benjamin F. Edwards & Company first reported a position in CNCE in Q1 2016 and held it in 6 quarters. The position peaked at $5K in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

  • Benjamin F. Edwards & Company reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 300 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $4K.
  • Benjamin F. Edwards & Company first reported a position in Concert Pharmaceuticals, Inc. in Q1 2016 and held it in 6 quarters.
  • Benjamin F. Edwards & Company's Concert Pharmaceuticals, Inc. position peaked at $5K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2017, filed 24 Oct 2017.